Next 10 |
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cidara Therapeutics, Inc. ("Cidara" or "the Company") (NASDAQ:CDTX). Investors who purchased Cidara securities are encouraged to obtain additional informa...
2024-04-26 18:01:25 ET Summary Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition of CD388 from Janssen, CDTX is well funded to star...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...
A look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 52.1% to $0.2192 on volume of 34,842,044 shares Processa Pharmaceuticals Inc. (PCSA) rose 46.9% to $2.38 on volume of 31,858,013 shares PROSHARES TRUST (SQQQ) rose 5.0% to $12.4002 on volume...
2024-04-24 16:45:57 ET More on Cidara Therapeutics Cidara Therapeutics GAAP EPS of -$0.04 beats by $0.06, revenue of $17.6M beats by $6.06M Cidara Therapeutics announces receipt of Nasdaq delinquency notice Seeking Alpha’s Quant Rating on Cidara Therapeutics ...
A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 179.3% to $0.4253 on volume of 213,352,319 shares Tesla Inc. (TSLA) rose 12.1% to $162.13 on volume of 179,967,315 shares PROSHARES TRUST (SQQQ) fell 0.8% to $11.81 on volume of...
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being deve...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungi...
A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 43.1% to $0.218 on volume of 39,190,339 shares Amesite Inc. (AMST) rose 100.0% to $4.0001 on volume of 36,290,765 shares Tesla Inc. (TSLA) rose 10.7% to $160.21 on volume of 32,...
2024-04-24 09:02:03 ET Cidara Therapeutics Inc (CDTX) announced stock split at a ratio of 1-for-20 on 2024-04-24 ... Full story available on KlickAnalytics.com
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cidara Therapeutics, Inc. ("Cidara" or "the Company") (NASDAQ:CDTX). Investors who purchased Cidara securities are encouraged to obtain additional informa...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak&...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...